The prevalence of Huntington’s disease (HD) is about 4-10 per 100.000
with roughly 4-5 times as many – in Europe this is about 150.000 people –
being at risk of developing the disease. At present we witness an
increasing number of clinical trials with novel therapeutics. This gives
us much hope that the treatment of those with HD will improve in the
foreseeable future. The Holy Grail, however, would be something that
prevented HD in someone carrying the gene. Inevitably, this will have to
involve healthy individuals carrying the HD gene in clinical trials.
There is therefore an increasing interest/need to study this population
of individuals including the development of novel tools for clinical
assessment in these future trials. Yet young adults who are ‘at-risk’,
HD gene carriers or have had a negative genetic test are often
overlooked in the services which are provided for people with HD, and
few young adults are currently participating in ongoing clinical studies
such as REGISTRY.
At risk also means these individuals grow up
in a family with HD under the Damocles’ sword of having, or not,
inherited the HD gene mutation. Young adults with HD in the family often
feel ‘alone in the midst of others’ (Sharpel et al 2008); while they
have friends, they describe them as being unable to really understand
what it’s like to live with HD. This population needs genetic
counselling, advice on important life decisions and treatment of medical
conditions. We know too little about other needs. Better knowledge may
inform best clinical practice and a standard set up of a clinic
dedicated to these individuals. Support networks for young adults are
missing in many countries. The YAWG itself will not form a support
group, but would aim to enable young adults to create support networks
in the countries they represent
Encuesta para los jóvenes de familias de Huntington